Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

#4421

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Aim(s): To compare 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with G1-G3 neuroendocrine tumours.

Materials and methods: 41 patients with biopsy-proven neuroendocrine tumours were enrolled in this prospective study. All patients underwent 68Ga-DOTATATE PET/CT and 18F-AlF-NOTA-JR11 PET/MR successively. The biodistribution, the lesion number, SUVmax and tumour-to-liver ratio (TLR) were measured and compared.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,